Despite numerous advances in treatments for cardiovascular disease, heart failure (HF)
remains the leading cause of death worldwide. A significant factor contributing to the …

La cardiomyopathie diabétique est définie comme une dysfonction ventriculaire du c ur du
diabétique en l'absence de coronaropathie. À l'aide de techniques in vivo et ex vivo …

OBJECTIVE Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat type 2
diabetes, and transient GLP-1 administration improved cardiac function in humans after …

Background—Exaggerated and prolonged inflammation after myocardial infarction (MI)
accelerates left ventricular remodeling. Inflammatory pathways may present a therapeutic …

Murine models have been utilized with increasing frequency mainly due to availability of
genetically engineered models. With advancement in high spatial and temporal resolution …

Objectives: The aim of this study was to explore post–myocardial infarction (MI) myocardial
inflammation. Background: Innate immune cells are centrally involved in infarct healing and …

Objectives: The aim of this study was to test whether blood monocytosis in mice with
atherosclerosis affects infarct healing. Background: Monocytes are cellular protagonists of …

Rationale: High-sensitivity in vivo phenotyping of cardiac function is essential for evaluating
genes of interest and novel therapies in small animal models of cardiovascular disease …

Following myocardial infarction, nonischemic myocyte death results in infarct expansion,
myocardial loss, and ventricular dysfunction. Here, we demonstrate that a specific …

The ability to image cardiomyocyte apoptosis in vivo with high‐resolution MRI could facilitate
the development of novel cardioprotective therapies. The sensitivity of the novel …